Single Dose Antibiotic as Effective in Treating Skin Diseases as Twice-Daily Infusion

Researchers at Duke Medicine have found that a new single-dose antibiotic was as effective in treating stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), as a twice-daily infusion given for up to 10 days.

Researchers said the advantage of the new drug, oritavancin, is its potential to curtail what has been a key driver of antibiotic resistance: a tendency for patients to stop taking antibiotics once they feel better. In such instances, the surviving bacteria may become impervious to the drugs designed to fight them.

MRSA “Super bug” – Symptoms - Risk Factors – Diagnosis - Treatment
MRSA infection is the most dreaded hospital or community acquired infection that can become life-threatening.

"The prolonged activity is what makes oritavancin distinctive," said G. Ralph Corey, M.D., lead author of the study published June 5, 2014, in the New England Journal of Medicine (NEJM). "This drug has a long half-life, which allows for a single-dose treatment."

Corey, a professor of medicine and infectious diseases at Duke University School of Medicine, led a three-year study of oritavancin that encompassed two large clinical trials enrolling nearly 2,000 patients. Findings from the trials will be presented to the U.S. Food and Drug Administration as part of the drug's approval application.

Results reported in the NEJM are for the first of the two clinical trials, which included 475 patients randomized to take the investigational drug, and 479 patients following a typical regimen of vancomycin, including two infusions a day, for seven to 10 days.

Drug Resistance – Antibiotic or Antimicrobial Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and hospital acquired diseases. Judicious use of antibiotics can control the problem.

Researchers found that the single intravenous dose of oritavancin was as effective as vancomycin in shrinking the size of the lesion and reducing fever. Both were also similar in rates of requiring a rescue antibiotic.

The new antibiotic also performed similarly to vancomycin in reducing the area of the wound by 20 percent or more within the first 48-72 hours of treatment, and in curing the patients of infection, including those infected with MRSA.

MRSA Rates Varied Dramatically Among Academic Medical Centers
The rates of community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) varied dramatically among academic medical centers in California, New York, Illinois and North Carolina.

"Having a single-dose drug could potentially prevent hospitalizations or reduce the amount of time patients would spend in the hospital," Corey said.
Source-Eurekalert

In MRSA, Receptor Proteins may Hold Clues to Antibiotic Resistance
At Imperial College London, scientists have identified four new proteins that act as receptors for an essential signalling molecule in bacteria such as MRSA.